Financhill
Buy
63

VTR Quote, Financials, Valuation and Earnings

Last price:
$77.53
Seasonality move :
2.56%
Day range:
$77.28 - $78.19
52-week range:
$56.68 - $81.89
Dividend yield:
2.48%
P/E ratio:
146.25x
P/S ratio:
6.26x
P/B ratio:
2.94x
Volume:
2.4M
Avg. volume:
3.1M
1-year change:
31.4%
Market cap:
$36.3B
Revenue:
$4.9B
EPS (TTM):
$0.53

Analysts' Opinion

  • Consensus Rating
    Ventas, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 13 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $85.15, Ventas, Inc. has an estimated upside of 10.04% from its current price of $77.38.
  • Price Target Downside
    According to analysts, the lowest downside price target is $75.00 representing 100% downside risk from its current price of $77.38.

Fair Value

  • According to the consensus of 17 analysts, Ventas, Inc. has 10.04% upside to fair value with a price target of $85.15 per share.

VTR vs. S&P 500

  • Over the past 5 trading days, Ventas, Inc. has underperformed the S&P 500 by -0.37% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Ventas, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Ventas, Inc. has grown year-over-year revenues for 17 quarters straight. In the most recent quarter Ventas, Inc. reported revenues of $1.5B.

Earnings Growth

  • Ventas, Inc. has grown year-over-year earnings for 5 quarters straight. In the most recent quarter Ventas, Inc. reported earnings per share of $0.14.
Enterprise value:
49.4B
EV / Invested capital:
--
Price / LTM sales:
6.26x
EV / EBIT:
57.23x
EV / Revenue:
8.89x
PEG ratio (5yr expected):
-20.68x
EV / Free cash flow:
39.79x
Price / Operating cash flow:
28.01x
Enterprise value / EBITDA:
23.58x
Gross Profit (TTM):
$1.1B
Return On Assets:
0.94%
Net Income Margin (TTM):
4.45%
Return On Equity:
2.14%
Return On Invested Capital:
0.99%
Operating Margin:
15.88%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Income Statement
Revenue $4.4B $4.8B $5.6B $1.2B $1.5B
Gross Profit -$53.7M $3.6M $1.1B $234.4M $290.2M
Operating Income -$226.9M -$142.6M $862.7M $195.4M $236.5M
EBITDA $1.7B $1.9B $2.1B $482.4M $565.3M
Diluted EPS $0.01 -$0.17 $0.53 $0.05 $0.14
Period Ending 2021-09-30 2022-09-30 2023-09-30 2024-09-30 2025-09-30
Balance Sheet
Current Assets $686.9M $477.3M $727.1M $1.4B $647.9M
Total Assets $25B $24.3B $25B $25.3B $26.9B
Current Liabilities $789.2M $479.6M $208.5M $176M $224.3M
Total Liabilities $13.6B $13.6B $14.8B $15.2B $14.2B
Total Equity $11.4B $10.7B $10.1B $10.2B $12.8B
Total Debt $12.4B $12.5B $13.7B $14B $12.9B
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Cash Flow Statement
Cash Flow Operations $1.2B $1.2B $1.6B $356.2M $378.6M
Cash From Investing -$333.6M -$885.1M -$3.8B -$432M -$1.2B
Cash From Financing -$553.7M $321.9M $1.3B $624.4M $368.1M
Free Cash Flow $955M $944.5M $1.2B $284.1M $286.4M
VTR
Sector
Market Cap
$36.3B
$974.8M
Price % of 52-Week High
94.49%
86.99%
Dividend Yield
2.48%
2.45%
Shareholder Yield
-6.78%
3.12%
1-Year Price Total Return
31.4%
--
Beta (5-Year)
0.781
0.628
Dividend yield:
2.48%
Annualized payout:
$1.80
Payout ratio:
336.84%
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $79.06
200-day SMA
Buy
Level $69.28
Bollinger Bands (100)
Buy
Level 67.85 - 77.85
Chaikin Money Flow
Sell
Level -4.3M
20-day SMA
Sell
Level $79.16
Relative Strength Index (RSI14)
Sell
Level 42.39
ADX Line
Sell
Level 10.9
Williams %R
Neutral
Level -72.5664
50-day SMA
Buy
Level $77.21
MACD (12, 26)
Buy
Level 21.66
25-day Aroon Oscillator
Sell
Level -8
On Balance Volume
Sell
Level -5.2M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (0.9065)
Sell
CA Score (Annual)
Level (-0.7331)
Buy
Beneish M-Score (Annual)
Level (-3.3938)
Buy
Momentum Score
Level (6)
Buy
Ohlson Score
Level (-0.9274)
Buy
Piotroski F Score (Annual)
Level (8)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (6)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Ventas, Inc. engages in the acquisition and ownership of seniors housing and healthcare properties. It operates through the following segments: Senior Housing Operating Portfolio (SHOP), Outpatient Medical and Research Portfolio (OM&R), and Triple-net Leased Properties (NNN). The SHOP segment is involved in owning and investing in senior housing communities throughout the United States and Canada. The OM&R segment refers to acquiring, owning, development, leasing and managing outpatient medical buildings and research centers throughout the United States. The NNN segment focuses on investing and owning senior housing communities, skilled nursing facilities, long-term acute care facilities, freestanding inpatient rehabilitation facilities, and other healthcare facilities throughout the United States and the United Kingdom. The company was founded in 1983 and is headquartered in Chicago, IL.

Stock Forecast FAQ

In the current month, VTR has received 13 Buy ratings 4 Hold ratings, and 0 Sell ratings. The VTR average analyst price target in the past 3 months is $85.15.

  • Where Will Ventas, Inc. Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Ventas, Inc. share price will rise to $85.15 per share over the next 12 months.

  • What Do Analysts Say About Ventas, Inc.?

    Analysts are divided on their view about Ventas, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ventas, Inc. is a Sell and believe this share price will drop from its current level to $75.00.

  • What Is Ventas, Inc.'s Price Target?

    The price target for Ventas, Inc. over the next 1-year time period is forecast to be $85.15 according to 17 Wall Street analysts, 13 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.

  • Is VTR A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Ventas, Inc. is a Buy. 13 of 17 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of VTR?

    You can purchase shares of Ventas, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ventas, Inc. shares.

  • What Is The Ventas, Inc. Share Price Today?

    Ventas, Inc. was last trading at $77.53 per share. This represents the most recent stock quote for Ventas, Inc.. Yesterday, Ventas, Inc. closed at $77.38 per share.

  • How To Buy Ventas, Inc. Stock Online?

    In order to purchase Ventas, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Did Stan Druckenmiller Sell Broadcom Stock?
Why Did Stan Druckenmiller Sell Broadcom Stock?

In Q3, legendary macro investor Stan Druckenmiller sold his entire…

Why Is CoreWeave Stock Down So Much?
Why Is CoreWeave Stock Down So Much?

AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…

Why Did Stan Druckenmiller Buy MercadoLibre Stock?
Why Did Stan Druckenmiller Buy MercadoLibre Stock?

In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…

Stock Ideas

Buy
55
Is NVDA Stock a Buy?

Market Cap: $4.5T
P/E Ratio: 63x

Buy
53
Is AAPL Stock a Buy?

Market Cap: $4T
P/E Ratio: 36x

Buy
61
Is GOOG Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 39x

Alerts

Sell
30
CORT alert for Jan 2

Corcept Therapeutics, Inc. [CORT] is up 5.09% over the past day.

Buy
75
AXSM alert for Jan 2

Axsome Therapeutics, Inc. [AXSM] is down 3.81% over the past day.

Sell
50
NUTX alert for Jan 2

Nutex Health, Inc. [NUTX] is down 9.27% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock